Mission, Vision and Core Value

Mission, Vision and Core Value of the ACOS (draft)


ACOS aims to ensure the current best practice for Asian cancer patients by implementing multidisciplinary treatments. To achieve this mission, ACOS holds the following core values:


ACOS strongly hope that our Asian patients will be able to be free from cancer by multidisciplinary treatments.

Core Values

  1. to make a difference in Asian oncology through translational research and expert techniques.
  2. to rethink cancer therapy from palliative to curative.
  3. to highly motivate both of doctors and patients.
  4. to identify the best practices and do it at good timing.
  5. to develop less invasive and less expensive therapies.
  6. to bolster cancer prevention through education and early diagnosis.

Strategy and Philosophy to Achieve our Core Values

  1. Complete surgical resection: curative operation with expert surgeons technique and/or onco-surgical oncepts.
  2. Pre- and post-operative chemotherapy with or without radiotherapy.
  3. Give a better cancer therapy than now at good timing (clinical trial and evidence based medicine to attain the current best practices)
  4. Repeat tumor resection against responder case of the tumor metastases (conversion therapy, from palliative to curative)
  5. Induced the tumor dormancy state or long survival periods without tumor shrink using immunotherapy, vaccine therapy, gene therapy, stem cell therapy, etc.

Where we are

  1. Clarifying the epidemiologic character of Asian peoples, analyzing and assessing current methods of cancer diagnosis and therapy, and also clarifying the genetic significance of Asian peoples. ACOS published the commemorative book of 9th ACOS, entitled "Recent Advances of Cancer in Asian countries"
  2. Surgery is one of the most important methods to remove total cancer cells. Other recent advances in less invasive operation include Robotic surgery. This treatment shows significant improvement in cosmetics, is less invasive and shortens hospitalization, etc. From the perspective of cancer therapy, our most important tool is in managing cancer patients skillfully with high-trained teams of oncologists.
  3. To clarify the present status and future perspectives, we have to discuss with not only doctors, nurses, pharmacists but also patients.
  4. Asia has various forms of unique traditional medicine such as Chinese medicine, Oriental medicine, KAMPO, etc. These traditional drugs are highly developed and valued not only in Asia but around the world for their use in complementary alternative medicine (CAM). However, their chemical structure and pharmacological functions have yet to be clarified in a complete scientific sense. Therefore, we should research and develop these traditional medicine by combining them with western high technological support.
  5. To make a specific guideline for Asian cancer patients, the first step might be revised from the NCCN Clinical Practice Guidelines in Oncology to fixed Asian economical and genetic situation.
  6. Japanese Pharmaceutical company technologies have produced two major oral anti-cancer drugs, such as Zeloda and TS-1.